{"id":22589,"date":"2024-05-24T16:53:25","date_gmt":"2024-05-24T07:53:25","guid":{"rendered":"https:\/\/plaza.umin.ac.jp\/sawamura\/?p=22589"},"modified":"2024-11-19T12:28:29","modified_gmt":"2024-11-19T03:28:29","slug":"braf","status":"publish","type":"post","link":"https:\/\/plaza.umin.ac.jp\/sawamura\/pediattumor\/braf\/","title":{"rendered":"\u5c0f\u5150\u8133\u816b\u760d\u3068BRAF\uff08\u30d3\u30fc\u30e9\u30d5\uff09\u907a\u4f1d\u5b50"},"content":{"rendered":"<ul>\n<li>BRAF\u907a\u4f1d\u5b50\u306e\u7570\u5e38\u3067\u767a\u751f\u3059\u308b\u764c\u306b\u306f\uff0c\u60aa\u6027\u9ed2\u8272\u816b\uff0c\u6709\u6bdb\u7d30\u80de\u767d\u8840\u75c5\uff0c\u7532\u72b6\u817a\u30ac\u30f3\uff0c\u5927\u8178\u30ac\u30f3\u3084\u80ba\u30ac\u30f3\u304c\u6709\u540d\u3067\u3059<\/li>\n<li>\u8133\u816b\u760d\u306b\u3082BRAF\u907a\u4f1d\u5b50\u306e\u7570\u5e38\u3067\u767a\u751f\u3059\u308b\u3082\u306e\u304c\u3042\u308b\u3053\u3068\u304c\u77e5\u3089\u308c\u3066\u304d\u307e\u3057\u305f<\/li>\n<li>\u7279\u306b\u5c0f\u5150\u306e\u8133\u816b\u760d\u3067BRAF\u306e\u907a\u4f1d\u5b50\u7570\u5e38\u306f\u591a\u3044\u3067\u3059<\/li>\n<li>\u4f4e\u60aa\u6027\u5ea6\u795e\u7d4c\u81a0\u816b low-grade glioma\u306e\u4e2d\u3067\u306f\u3082\u3063\u3068\u3082\u983b\u5ea6\u304c\u9ad8\u3044\u907a\u4f1d\u5b50\u7570\u5e38\u3067\uff0cLGG\u306e\u534a\u6570\u4ee5\u4e0a\u306b\u3053\u306e\u907a\u4f1d\u5b50\u7570\u5e38\u304c\u3042\u308b\u3068\u3082\u8a00\u308f\u308c\u307e\u3059<\/li>\n<\/ul>\n<h5>BRAF\u907a\u4f1d\u5b50\u306b\u7570\u5e38\u304c\u3042\u308b\u3068\u30ac\u30f3\u306b\u306a\u308b\u7406\u7531<\/h5>\n<ul>\n<li>BRAF\u907a\u4f1d\u5b50\u3068\u3044\u3046\u306e\u306f\u9577\u3044\u907a\u4f1d\u5b50\u3067\uff0c\u305d\u306e<span style=\"color: #000080;\"><strong>\u30b3\u30c9\u30f3600\u756a\u76ee\u306e\u30a2\u30df\u30ce\u9178 (\u30d0\u30ea\u30f3V) \u00a0V600E <\/strong><\/span>\u306e\u70b9\u7a81\u7136\u5909\u7570\u304c\u307b\u3068\u3093\u3069\u3067\u3059<\/li>\n<li>\u4ed6\u306b\u306f<span style=\"color: #000080;\"><strong>BRAF\u878d\u5408<\/strong><\/span>\u306a\u3069\u306e\u7570\u5e38\u3082\u3042\u308a\u307e\u3059<\/li>\n<li>\u305d\u3046\u3059\u308b\u3068\uff0c\u907a\u4f1d\u5b50\u306e\u547d\u4ee4\u3067\u3067\u304d\u308b<span style=\"color: #000080;\"><strong>BRAF\u5206\u5b50\u304c\u5e38\u306b\u6d3b\u6027\u5316<\/strong><\/span>\u3057\u3066\u3057\u307e\u3044\u307e\u3059<\/li>\n<li>BRAF\u86cb\u767d\u306e\u6d3b\u6027\u5316\u304c\u7d9a\u304f\u3068\uff0c\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u7d4c\u8def\u3067\u3042\u308bMEK-ERK (MAPK) \u7d4c\u8def\u304c\u904e\u5270\u306b\u6d3b\u6027\u5316\u3057\u307e\u3059<\/li>\n<li><strong><span style=\"color: #000080;\">MARK\u7d4c\u8def\u306e\u6d3b\u6027\u5316\u306f\uff0c\u7d30\u80de\u3092\u5897\u6b96\u3055\u305b\u3066\u30ac\u30f3\u7d30\u80de\u3092\u7121\u5236\u9650\u306b\u5897\u3084\u3057\u307e\u3059<\/span><\/strong><\/li>\n<li><span style=\"color: #000080;\"><strong><span class=\"linkitpup\">BRAF\u963b\u5bb3\u85ac<\/span><\/strong><\/span>\u306f\u3053\u306eV600E\u5909\u7570\u306b\u3088\u308b\u304c\u3093\u306e\u5897\u6b96\u3092\u6291\u3048\u308b\u85ac\u3067\u3059<\/li>\n<li>BRAF\u963b\u5bb3\u85ac\u3060\u3051\u3092\u6295\u4e0e\u3057\u305f\u5834\u5408\u3001<span style=\"color: #000080;\"><strong>MEK\u907a\u4f1d\u5b50\u304c\u4e0a\u6d41\u306e<span class=\"linkitpup\">RAS\u907a\u4f1d\u5b50\uff08\u30ac\u30f3\u907a\u4f1d\u5b50\uff09<\/span>\u306e\u6a5f\u80fd\u3092\u6291\u3048\u3066\u3044\u308b<\/strong><\/span>\u3053\u3068\u307e\u3067\u969c\u5bb3\u3055\u308c\u308b\u305f\u3081\u3001\u9006\u306b\u30ac\u30f3\u304c\u5927\u304d\u304f\u306a\u3063\u305f\u308a\u3059\u308b\u3053\u3068\u304c\u3042\u308a\u307e\u3059<\/li>\n<li>\u3060\u304b\u3089\uff0c\u4e00\u7dd2\u306b<span style=\"color: #000080;\"><strong>MEK\u963b\u5bb3\u85ac\u3092\u4f75\u7528\u3059\u308b<\/strong><\/span>\u3068\u305d\u3046\u3044\u3063\u305f\u5f0a\u5bb3\u304c\u6291\u3048\u3089\u308c\u307e\u3059<\/li>\n<li>BRAFV600\u907a\u4f1d\u5b50\u5909\u7570\u967d\u6027\u306e\u8133\u816b\u760d\u306e\u85ac\u7269\u7642\u6cd5\u306f\u3001<span style=\"color: #000080;\"><strong>BRAF\u963b\u5bb3\u85ac\u3068MEK\u963b\u5bb3\u85ac\u306e<span class=\"linkitpup\">\u4f75\u7528\u7642\u6cd5<\/span><\/strong><\/span>\u304c\u9078\u629e\u80a2\u3068\u306a\u308a\u307e\u3059<\/li>\n<li>\u554f\u984c\u306f\uff0c\u3044\u3063\u3068\u304d\u6709\u52b9\u3067\u3042\u3063\u305f\u4f8b\u3067\u3082\u3053\u306e\u6cbb\u7642\u304c\u52b9\u304b\u306a\u304f\u306a\u3063\u3066\u3057\u307e\u3046\u3053\u3068\u3067\u3059<\/li>\n<\/ul>\n<h5>BRAF\u878d\u5408\u907a\u4f1d\u5b50\u7570\u5e38<\/h5>\n<ul>\n<li>BRAF-V600E\u306e\u907a\u4f1d\u5b50\u5909\u7570\u304c\u307b\u3068\u3093\u3069\u306a\u306e\u3067\u3059\u304c\uff0cBRAF\u907a\u4f1d\u5b50\u306e\u878d\u5408\u306b\u3088\u3063\u3066\u751f\u3058\u308b\u816b\u760d\u304c\u7a00\u306b\u3042\u308a\u307e\u3059<\/li>\n<li>\u6bdb\u69d8\u7d30\u80de\u6027\u661f\u7d30\u80de\u816b\u304c\u4ee3\u8868\u7684\u306a\u816b\u760d\u3067\u3059<\/li>\n<\/ul>\n<h5>\u6cbb\u7642<\/h5>\n<h4><span style=\"color: #000080;\"><strong>\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\u3068\u30c8\u30e9\u30e1\u30c1\u30cb\u30d6<\/strong><\/span><\/h4>\n<p><span style=\"color: #000080;\"><strong>BRAF v600\u907a\u4f1d\u5b50\u306b\u5909\u7570<\/strong><\/span>\u306e\u3042\u308b\u4f8b\u3067\uff0c<span style=\"color: #000080;\"><strong>\u30bf\u30d5\u30a3\u30f3\u30e9\u30fc\u30ab\u30d7\u30bb\u30eb\uff08<\/strong><strong>\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\uff0cDabrafenib, BRAF\u963b\u5bb3\u5264\uff09\u3068\u30e1\u30ad\u30cb\u30b9\u30c8\u9320\uff08\u30c8\u30e9\u30e1\u30c1\u30cb\u30d6\uff0cTrametinib, MEK\u963b\u5bb3\u5264\uff09<\/strong><\/span>\u3092\u7d4c\u53e3\u6295\u4e0e\u3057\u307e<br \/>\n<a href=\"https:\/\/theibta.us8.list-manage.com\/track\/click?u=9487f42621af3144e7c7ddc6e&amp;id=70e503b054&amp;e=049a46fa84\">\u6b27\u7c73\u3067\u306f1\u6b73\u4ee5\u4e0a\u306e\u5c0f\u5150\u306b\u81ea\u5b85\u3067\u670d\u7528\u3059\u308b\u305f\u3081\u306e\u6307\u5c0e\u8981\u9818\u304c\u3042\u308a\u307e\u3059<\/a><\/p>\n<h4><strong>\u30c8\u30dc\u30e9\u30d5\u30a7\u30cb\u30d6<\/strong><\/h4>\n<p><span style=\"color: #000080;\"><strong>tovorafenib (Ojemda)<\/strong><span style=\"color: #333333;\">\u306f\uff0c\u9031\u306b\u4e00\u56de\u7d4c\u53e3\u6295\u4e0e\u3057\u3066\u7528\u3044\u308btype II RAF inhibitor\u3067\u3059\u3002<\/span><\/span>BRAF\u306b\u7570\u5e38\uff08\u878d\u5408 fusion\uff0cV600\u5909\u7570\u3042\u308b\u3044\u306frearrangement\uff09\u306e\u3042\u308b\u5c0f\u5150\u306e\u4f4e\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u306b\u5bfe\u3057\u306651\uff05\u3067\u4f55\u3089\u304b\u306e\u52b9\u679c\u304c\u898b\u3089\u308c\u305f\u3068\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u3059<\/p>\n<h4><strong>\u30d3\u30cb\u30e1\u30c1\u30cb\u30d6<\/strong><\/h4>\n<p>BRAF\u878d\u5408\u907a\u4f1d\u5b50\u967d\u6027\u4f8b\u3067\u306f\uff0cONO-7703\uff08<strong>\u30d3\u30cb\u30e1\u30c1\u30cb\u30d6\uff0c<span style=\"color: #000080;\">MEK\u963b\u5bb3\u5264\uff09<\/span><\/strong>\u306e\u81e8\u5e8a\u8a66\u9a13\u304c\u958b\u59cb\u3055\u308c\u307e\u3057\u305f<\/p>\n<h5>\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\u3068\u30c8\u30e9\u30e1\u30c1\u30cb\u30d6\u306e\u65e5\u672c\u3067\u306e\u6cbb\u9a13\u3068\u4f7f\u7528\uff082024\u5e74\uff09<\/h5>\n<ul>\n<li><strong>\u5f93\u6765\u306e\u6cbb\u7642\u306b\u62b5\u6297\u6027\u306e\u3082\u306e\u306b\u306f\uff0cBRAF\u963b\u5bb3\u5264\u306e\u30bf\u30d5\u30a3\u30f3\u30e9\u30fc\uff08\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6)\u3068\u30e1\u30ad\u30cb\u30b9\u30c8\uff08\u30c8\u30e9\u30e1\u30c1\u30cb\u30d6\uff09\u306e\u4f75\u7528\u6295\u4e0e\u304c\u4fdd\u967a\u8a3a\u7642\u3067\u3067\u304d\u307e\u3059<\/strong><\/li>\n<li>BRAF v600\u907a\u4f1d\u5b50\u306b\u5909\u7570\u306e\u3042\u308b\u4f8b\u3067\uff0c<strong>\u30bf\u30d5\u30a3\u30f3\u30e9\u30fc\u30ab\u30d7\u30bb\u30eb\uff08<\/strong><strong>\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\uff0cBRAF\u963b\u5bb3\u5264\uff09\uff0c\u30e1\u30ad\u30cb\u30b9\u30c8\u9320\uff08<\/strong><strong>\u30c8\u30e9\u30e1\u30c1\u30cb\u30d6\uff0cMEK\u963b\u5bb3\u5264\uff09<\/strong>\u3092\u7d4c\u53e3\u6295\u4e0e\u3059\u308b\u3082\u306e\u3067\u3059<\/li>\n<li>2023\u5e74\u6642\u70b9\u3067\u3082\u3063\u3068\u3082\u671f\u5f85\u3092\u6301\u3063\u3066\u81e8\u5e8a\u4f7f\u7528\u304c\u3055\u308c\u3066\u3044\u308b\u6a19\u7684\u6cbb\u7642\u3067\u3059<\/li>\n<li>\u3067\u3082<strong>BRAF\u5909\u7570\u306f\u6bdb\u69d8\u7d30\u80de\u6027\u661f\u7d30\u80de\u816b\u306e3 \u2013 10%\u304f\u3089\u3044\u306b\u3057\u304b\u306a\u3044<\/strong>\u3067\u3059<\/li>\n<\/ul>\n<ul>\n<li>BRAF v600\u5909\u7570\u304c\u3042\u308b\u816b\u760d\u3092\u6709\u3059\u308b15\u6b73\u4ee5\u4e0b\u306e\u5c0f\u5150\u306b\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\u30fb\u30c8\u30e9\u30e1\u30c1\u30cb\u30d6\u6295\u4e0e\u3057\u307e\u3059<\/li>\n<li>\u6cbb\u9a13\u306f\uff0c\u6749\u5c71\u672a\u5948\u5b50\u5148\u751f\u304c\u62c5\u5f53\u8005\u3067\u3059<\/li>\n<\/ul>\n<h5><a href=\"https:\/\/ct.ganjoho.jp\/category\/ttrial\/jRCTs011220017\">RAF V600\u5909\u7570\u967d\u6027\u5c40\u6240\u9032\u884c\u30fb\u8ee2\u79fb\u6027\u5c0f\u5150\u56fa\u5f62\u816b\u760d\u306b\u5bfe\u3059\u308b\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\u30fb\u30c8\u30e9\u30e1\u30c1\u30cb\u30d6\u306e\u7b2cII\u76f8\u8a66\u9a13\u3000\uff08jRCTs011220017\uff09<br \/>\n\uff08\u30af\u30ea\u30c3\u30af\u3059\u308b\u3068\u958b\u304d\u307e\u3059\uff09<\/a><\/h5>\n<h5>BRAF\u907a\u4f1d\u5b50\u306b\u7570\u5e38\u3092\u6709\u3059\u308b\u816b\u760d<\/h5>\n<ul>\n<li>pleomorphic xanthoastrocytoma<\/li>\n<li>ganglioglioma<\/li>\n<li>pilocytic astrocytoma<\/li>\n<li>diffuse midline glioma: H3 K27M-mutant co-occurred with\u00a0BRAF-V600E mutation<\/li>\n<li>craniopharyngioma papillary type<\/li>\n<li>epithelioid\/rhabdoid \u00a0GBM<\/li>\n<li>diffuse leptomeningeal glioneuronal tumor DLGNT: BRAF fusion<\/li>\n<\/ul>\n<h5><\/h5>\n<h5>\u52b9\u679c<\/h5>\n<ul>\n<li>BRAF-V600E mutation\u306b\u5bfe\u3057\u3066\u306f\uff0c40\uff05\u304f\u3089\u3044\u306e\u4f8b\u30672\u5e74\u9593\u304f\u3089\u3044\u6709\u52b9\u3068\u3055\u308c\u3066\u3044\u307e\u3059\u304c\uff0c\u307e\u3060\u306f\u3063\u304d\u308a\u3057\u3066\u3044\u307e\u305b\u3093<\/li>\n<\/ul>\n<h5><strong>BRAF v600\u5909\u7570\u306e\u3042\u308b\u30b0\u30ea\u30aa\u30fc\u30de\u3068\u305d\u306e\u6bd4\u7387<\/strong><\/h5>\n<p>Andrews LJ: Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. Neuro Oncol 2022<\/p>\n<p>1. epithelioid glioblastoma (eGBM) : 69%<br \/>\n2. <strong>pleomorphic xanthoastrocytoma (PXA) : 56%<\/strong><br \/>\n3. <strong>anaplastic pleomorphic xanthoastrocytoma (aPXA) : 38%<\/strong><br \/>\n4. <strong>ganglioglioma (GG) : 40%<\/strong><br \/>\n5. <strong>anaplastic ganglioglioma (aGG) : 46%<\/strong><br \/>\n6. Prevalence in astroblastoma : 24%<br \/>\n7. desmoplastic infantile astrocytoma (DIA) : 16%<br \/>\n9. subependymal giant cell astrocytoma (SEGA) : 8%<br \/>\n10 dysembryoplastic neuroepithelial tumor (DNET): 3%<br \/>\n11 diffuse astrocytoma (DA) : 3%<br \/>\n12 pilocytic astrocytoma (PA) : 3% \uff08\u6ce8\uff1a\u3068\u3066\u3082\u4f4e\u3044\u5272\u5408\u3068\u306a\u3063\u3066\u3044\u307e\u3059\uff09<\/p>\n<h5>\u6587\u732e<\/h5>\n<div class=\"article-citation\">\n<h4><span style=\"color: #333333;\">tovorafenib\u306f\u6cbb\u7642\u62b5\u6297\u6027\u306e<\/span>\u5c0f\u5150\u306e\u4f4e\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de pLGG\u306e51%\u306b\u6709\u52b9\u6027\u3092\u793a\u3057\u305f<\/h4>\n<\/div>\n<p class=\"heading-title\"><span class=\"docsum-authors full-authors\">Kilburn LB:\u00a0<\/span>The <span style=\"color: #000080;\"><strong>type II RAF inhibitor tovorafenib<\/strong><\/span> in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.Nat Med, 2024<br \/>\nBRAF\u907a\u4f1d\u5b50\u306b\u4f55\u3089\u304b\u306e\u7570\u5e38\u304c\u3042\u308b\u518d\u767a\u3082\u3057\u304f\u306f\u6cbb\u7642\u62b5\u6297\u6027\u306e\u5c0f\u5150\u4f4e\u60aa\u5236\u5ea6\u795e\u7d4c\u81a0\u816b LGG\u306e\u60a3\u800577\u540d\u306b<span style=\"color: #000080;\"><strong>tovorafenib<\/strong><\/span> {type II RAF inhibitor tovorafenib (420 mg m<sup>&#8211;<\/sup><sup>2<\/sup> once weekly; 600 mg maximum)}\u306e\u6295\u4e0e\u304c\u306a\u3055\u308c\u307e\u3057\u305f\u3002ORR\u306f67% , median duration of response (DOR) 16.6 months; and median time to response (TTR) 3.0 months\u3067\u3057\u305f\u3002RR\u53cd\u5fdc\u3057\u305f\u75c7\u4f8b\u304c67\uff05\u306b\u3082\u53ca\u3076\u3068\u3044\u3046\u3053\u3068\u3067\u3059\u3002\u3055\u3089\u306b60\u4f8b\u304c\u8ffd\u52a0\u767b\u9332\u3055\u308c\uff0c\u8a08137\u4f8b\u3067\u306e\u89e3\u6790\u3067\u306f\uff0c<strong><span style=\"color: #000080;\">ORR 51%,<\/span><\/strong> median DOR 13.8 months; and median TTR 5.3 months\u3067\u3057\u305f\u3002\u6700\u3082\u591a\u304f\u898b\u3089\u308c\u305f\u526f\u4f5c\u7528\u306f\u9aea\u306e\u6bdb\u306e\u8272\u306e\u5909\u5316 76%\uff0cCPK\u306e\u4e0a\u6607\uff0c\u8ca7\u8840\u3067\u3057\u305f\u3002<\/p>\n<h4>BRAF\u878d\u5408\u306e\u4f8b\u3067\u3082tovorafenib\u304c\u6709\u52b9\u304b\u3069\u3046\u304b\u306e\u8a66\u9a13\u3082\u958b\u59cb\u3055\u308c\u307e\u3057\u305f<\/h4>\n<p><span class=\"authors-list-item \">van Tilburg CM:\u00a0<\/span>LOGGIC\/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. BMC Cancer, 2024<br \/>\n\u5316\u5b66\u7642\u6cd5\u3068\u306e\u6bd4\u8f03\u8a66\u9a13\uff0c\u7b2c3\u76f8\u8a66\u9a13\u3067\u3059\u304c\u7d50\u679c\u306f\u307e\u3060\u51fa\u3066\u3044\u307e\u305b\u3093\u3002<\/p>\n<h4><i>BRAF<\/i> V600 mutation\u306e\u3042\u308b\u4f4e\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u306b\u306f\uff0c\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\u3068\u30c8\u30e9\u30e1\u30c1\u30cb\u30d6\u3068\u306e\u4f75\u7528\u304c\u6709\u52b9<\/h4>\n<p class=\"heading-title\"><span class=\"authors-list-item \">Bouffet E:\u00a0<\/span>Dabrafenib plus Trametinib in Pediatric Glioma with <i>BRAF<\/i> V600 Mutations. N Engl J Med 2023<br \/>\n\u4e0b\u8a18\u306e\u5b66\u4f1a\u767a\u8868\u304c\u8ad6\u6587\u3068\u306a\u308a\u307e\u3057\u305f\u3002\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\u306f\u5358\u72ec\u3042\u308b\u3044\u306f\u30c8\u30e9\u30e1\u30c1\u30cb\u30d6\u3068\u306e\u4f75\u7528\u3067\uff0c<i>BRAF<\/i> V600 mutation\u3092\u6709\u3059\u308b\u4f4e\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u306b\u6709\u52b9\u306a\u3053\u3068\u304c\u77e5\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\/\u30c8\u30e9\u30e1\u30c1\u30cb\u30d6\u3068CBDCA\/VCR\u306e\u52b9\u679c\u304c\u6bd4\u8f03\u3055\u308c\u307e\u3057\u305f\u3002CBDCA\/VCR\u306f\u65e7\u6765\u5c0f\u5150\u306e\u30b0\u30ea\u30aa\u30fc\u30de\u306b\u6700\u3082\u4f7f\u7528\u3055\u308c\u305f\u4f75\u7528\u5316\u5b66\u7642\u6cd5\u3067\u3059\u3002\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\/\u30c8\u30e9\u30e1\u30c1\u30cb\u30d6\u306744%\uff0cCBDCA\/VCR\u306711%\u306e\u594f\u529f\u7387 (CR or PR)\u304c\u5f97\u3089\u308c\u307e\u3057\u305f\u3002\u81e8\u5e8a\u7684\u306a\u5229\u70b9\u306f\u305d\u308c\u305e\u308c86%\u306846\uff05\u3067\u3057\u305f\u3002PFS\u4e2d\u592e\u5024\u306f20\u30f6\u6708\u30687.4\u30f6\u6708\u3067\u3057\u305f\u3002<br \/>\n\u300c\u4e00\u8a00\u300fPFS\u304c20\u30f6\u6708\u3068\u3044\u3046\u3053\u3068\u306f\uff0c2\u5e74\u3092\u5f85\u305f\u305a\u306b\u518d\u71c3\u3059\u308b\u3068\u3044\u3046\u3053\u3068\u3067\u3059\u3002\u3057\u304b\u3057\u6bdb\u69d8\u7d30\u80de\u6027\u661f\u7d30\u80de\u816b\u3067\u306f\uff0c\u671f\u5f85\u3067\u3059\u304c\uff0c\u6570\u5e74\u306e\u6642\u9593\u7a3c\u304e\u304c\u3067\u304d\u3066\uff0c\u305d\u306e\u5185\u306b\u518d\u5897\u5927\u3057\u306a\u3044\u816b\u760d spontaneous involution \u3068\u306a\u308b\u306e\u304b\u3082\u3057\u308c\u307e\u305b\u3093\u3002\u3082\u3046\u4e00\u3064\uff0c\u6bdb\u69d8\u7d30\u80de\u6027\u661f\u7d30\u80de\u816b\u306eCBDCA\/VCR\u306e\u594f\u529f\u7387\u306f11%\u3067\u306f\u306a\u304f\u3066\uff0c50\uff05\u3092\u8d85\u3048\u308b\u3067\u3057\u3087\u3046\u3002\u3067\u3059\u304b\u3089\uff0c\u3053\u306e\u6cbb\u9a13\u3067\u306fCBDCA\/VCR\u304c\u52b9\u304d\u3065\u3089\u3044\u816b\u760d\u7fa4\u304c\u5bfe\u8c61\u3068\u306a\u3063\u3066\u3044\u308b\u3053\u3068\u306b\u6ce8\u610f\u3067\u3059\u3002<\/p>\n<h4><i>BRAF<\/i> V600 mutation\u306e\u3042\u308b\u9ad8\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u306b\u306f\uff0c\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\u3068\u30c8\u30e9\u30e1\u30c1\u30cb\u30d6\u3068\u306e\u4f75\u7528\u304c\u3042\u308b\u7a0b\u5ea6\u6709\u52b9<\/h4>\n<p class=\"heading-title\"><span class=\"authors-list-item \">Hargrave DR:\u00a0<\/span>Phase II Trial of Dabrafenib Plus Trametinib in Relapsed\/Refractory <i>BRAF<\/i> V600-Mutant Pediatric High-Grade Glioma. J Clin Oncol 2023<br \/>\n<i>BRAF<\/i> V600 mutation\u306f\u5c0f\u5150\u60aa\u6027\u795e\u7d4c\u81a0\u816b\u306e8-10%\u306b\u8a8d\u3081\u3089\u308c\u307e\u3059\u300241\u4f8b\u306e\u518d\u767a\u3042\u308b\u3044\u306f\u6cbb\u7642\u62b5\u6297\u6027\u306e\u60aa\u6027\u30b0\u30ea\u30aa\u30fc\u30de\u304c\u5bfe\u8c61\u3067\u3059\u3002\u594f\u529f\u5272\u5408\u306f56%\uff0c\u53cd\u5fdc\u671f\u9593\u4e2d\u592e\u5024\u306f22\u30f6\u6708\u3067\u3057\u305f\u3002\u534a\u5206\u304f\u3089\u3044\u306e\u4f8b\u30672\u5e74\u5f31\u6709\u52b9\u3067\u3042\u308b\u3068\u3044\u3046\u7d50\u679c\u3067\u3059\u3002<\/p>\n<h4><span class=\"title_default\">\u30dc\u30e9\u30b7\u30c7\u30cb\u30d6 vorasidenib\u306f\uff0c\u30b0\u30ec\u30fc\u30c92\u306e\u661f\u7d30\u80de\u816b\u3068\u4e4f\u7a81\u8d77\u81a0\u816b\u306e\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\u3092\u5ef6\u9577\u3059\u308b\uff1a\u81e8\u5e8a\u7b2c3\u76f8\u8a66\u9a13\u306e\u7d50\u679c<\/span><\/h4>\n<p>Mellinghoff IK:\u00a0<span class=\"title_default\">Vorasidenib in IDH1- or IDH2-mutant low-Grade glioma. New Engl J Med 2023<br \/>\nvorasidenib\u306f\u3001\u5909\u7570\u578bIDH1\/2\u9175\u7d20\u306e\u4f5c\u7528\u3092\u963b\u5bb3\u3059\u308b\u7d4c\u53e3\u85ac\u3067\u3001\u816b\u760d\u306e2-\u30d2\u30c9\u30ed\u30ad\u30b7\u30b0\u30eb\u30bf\u30eb\u9178\uff082-HG\uff09\u309290\uff05\u4ee5\u4e0a\u4f4e\u4e0b\u3055\u305b\u307e\u3059\u3002\u7d4c\u53e3\u85ac\u3067\u3059\u304c\u8133\u5185\u79fb\u884c\u304c\u3088\u3044\u85ac\u5264\u3067\u3059\u3002\u8853\u5f8c\u306e\u6b8b\u5b58\u816b\u760d\u3042\u308b\u3044\u306f\u518d\u71c3 168\u4f8b\u306bvorasidenib (40 mg once daily) \u304c\u6295\u4e0e\u3055\u308c\u307e\u3057\u305f\u3002\u89b3\u5bdf\u671f\u9593\u4e2d\u592e\u502414.2\u30f6\u6708\u306e\u6642\u70b9\u3067\uff0c7\u5272\u306e\u60a3\u8005\u3055\u3093\u304cvorasidenib\u3042\u308b\u3044\u306f\u30d7\u30e9\u30bb\u30dc\u3092\u7d99\u7d9a\u670d\u7528\u3057\u3066\u3044\u307e\u3057\u305f\u3002PFS\u4e2d\u592e\u5024\u306f\uff0cvorasidenib\u306727.7\u30f6\u6708\uff0c\u30d7\u30e9\u30bb\u30dc\u306711.1\u30f6\u6708\u3067\u3057\u305f\u3002\u30b0\u30ec\u30fc\u30c93\u4ee5\u4e0a\u306e\u6709\u5bb3\u4e8b\u8c61\u306f22.8%\u3067\u307f\u3089\u308c\uff0cALT\u306e\u4e0a\u6607\u304c\u76ee\u7acb\u3063\u305f\u305d\u3046\u3067\u3059\u3002\u6709\u5bb3\u4e8b\u8c61\u306b\u3088\u308b\u4e2d\u6b62\u306f3.6%\u3067\u3057\u305f\u3002<\/span><\/p>\n<h4 class=\"heading-title\">vemurafenib\u304c\u6709\u52b9\u3067\u3042\u3063\u305f<\/h4>\n<p class=\"heading-title\">Lin Z : Effective treatment of a BRAF V600E-mutant epithelioid glioblastoma patient by vemurafenib: a case report. Anticancer Drugs 2022<br \/>\n37\u6b73\u7537\u6027\u3067\uff0cBRAFv600E\u3068TERT\u306e\u5909\u7570\u304c\u3042\u308a\u307e\u3057\u305f\u3002IDH wild-type\u3067\u3059\u3002vemurafenib\u304c\u6295\u4e0e\u3055\u308c\u624b\u8853\u5f8c\u6b8b\u5b58\u816b\u760d\u304c15\u30f6\u6708\u5897\u5927\u3057\u306a\u304b\u3063\u305f\u305d\u3046\u3067\u3059\u3002<\/p>\n<div class=\"setumei\">\n<h4><em>BRAF<\/em> V600\u907a\u4f1d\u5b50\u5909\u7570\u304c\u3042\u308b\u3082\u306e\u306bMARK\u963b\u5bb3\u5264\u304c\u6709\u52b9<\/h4>\n<\/div>\n<p id=\"page-title\" class=\"highwire-cite-title\">Berzero G: Sustained tumor control with MAPK inhibition in <em>BRAF<\/em> V600\u2013mutant adult glial and glioneuronal tumors. Neurology 2021<br \/>\nMARK\u963b\u5bb3\u5264 (RAFi\/MEKi)\u306e\u52b9\u679c\u3092\u691c\u8a3c\u3057\u305f\u8ad6\u6587\u3067\u3059\u3002\u518d\u767a\u3042\u308b\u3044\u306f\u64ad\u7a2e\u3057\u305f\uff0c\u6210\u4eba\u306e\u795e\u7d4c\u7bc0\u81a0\u816b9\u4f8b\uff0c\u591a\u578b\u9ec4\u8272\u8089\u82bd\u7a2e9\u4f8b\uff0c\u3073\u307e\u3093\u6027\u30b0\u30ea\u30aa\u30fc\u30de10\u4f8b\u306b\u3053\u306e\u6cbb\u7642\u304c\u306a\u3055\u308c\u3066\u3044\u307e\u3057\u305f\u3002\u5168\u3066\u306e\u4f8b\u304c\u9ad8\u60aa\u6027\u5ea6\u816b\u760d\u306e\u753b\u50cf\u6240\u898b\u3092\u6709\u3057\u3066\u3044\u307e\u3057\u305f\u3002vemurafenib, dabrafenib, cobimetinib, trametinib \u306a\u3069\u306e\u85ac\u5264\u304c\u4f7f\u7528\u3055\u308c\u3066\u3044\u307e\u3059\u300211\u4f8b39%\u306b\u660e\u3089\u304b\u306a\u816b\u760d\u7e2e\u5c0f(PR, CR) \u304c\u8a8d\u3081\u3089\u308c\u307e\u3057\u305f\u3002FPS\u306f18\u30f6\u6708\u3067\u3057\u305f\u3002<\/p>\n<h4>BRAF\u3068MEK-1\/2\u963b\u5bb3\u5264\u306e\u52b9\u679c<\/h4>\n<p class=\"heading-title\">Venkatesh A: Response to BRAF and MEK1\/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: A Case Report and Literature Review. Current Probl Cancer 2021<br \/>\ndabrafenib and trametinib\u306e\u6cbb\u7642\u3067\u9577\u671f\u306e\u594f\u529f\u304c\u3042\u3063\u305f\u3068\u306e\u75c7\u4f8b\u5831\u544a\u3067\u3059\u3002<\/p>\n<h4>\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\u304c\u6709\u52b9\u3067\u3042\u3063\u305f<\/h4>\n<p class=\"heading-title\">Mustansir F: Dabrafenib in BRAFV600E mutant pilocytic astrocytoma in a pediatric patient. Childs Nerv Syst 2020<br \/>\n\u8996\u8def\u6bdb\u69d8\u7d30\u80de\u6027\u661f\u7d30\u80de\u816b\u306e1\u4f8b\u306b\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\u304c\u6709\u52b9\u3067\u3042\u3063\u305f1\u4f8b\u5831\u544a\u3067\u3059\u3002<\/p>\n<h4>BRAF\u5909\u7570\u306e\u3042\u308b\u4f8b\u3067\u30bb\u30eb\u30e1\u30c6\u30a3\u30cb\u30d6 s<span class=\"highlight\">elumetinib<\/span>\u304c\u6709\u52b9\u3060\u3063\u305f<\/h4>\n<p>Fangusaro J:\u00a0<span class=\"highlight\">Selumetinib<\/span> in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade <span class=\"highlight\">glioma<\/span>: a multicentre, phase 2 trial.\u00a0<span role=\"menubar\">Lancet Oncol.<\/span> 2019<br \/>\nBRAF aberrations (KIAA1549-BRAF fusion or the BRAF<sup>V600E\u00a0<\/sup>mutation)\u304c\u3042\u308a\u5f93\u6765\u306e\u6cbb\u7642\u306b\u62b5\u6297\u6027\u306e\u6bdb\u69d8\u7d30\u80de\u6027\u661f\u7d30\u80de\u816b\u306b\uff0cMEK\u963b\u5bb3\u5264\u3067\u3042\u308b<span class=\"highlight\">selumetinib\u304c\u7d4c\u53e3\u6295\u4e0e\u3055\u308c\u307e\u3057\u305f\u300225\u4f8b\u4e2d9\u4f8b 36%\u3067sustained partial response\u304c\u5f97\u3089\u308c\u307e\u3057\u305f\u300211\u4f8b\u30673\u5e74\u307b\u3069\u5897\u60aa\u304c\u306a\u304b\u3063\u305f\u3068\u306e\u3053\u3068\u3067\u3059\u3002<\/span><\/p>\n<h4>V600E\u5909\u7570\u306e\u3042\u308b\u4f8b\u3067\u30d9\u30e0\u30e9\u30d5\u30a7\u30cb\u30d6\u304c\u6709\u52b9\u3060\u3063\u305f<\/h4>\n<p>Kaley T: BRAF Inhibition in BRAF<sup>V600<\/sup>-Mutant Gliomas: Results From the VE-BASKET Study.J Clin Oncol.\u00a02018<br \/>\nUpadhyaya SA: Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases.\u00a0<span lang=\"EN-US\">Childs Nerv Syst.\u00a02018<br \/>\n\u3053\u306e2\u3064\u306e\u8ad6\u6587\u306f\uff0cBRAF-V600E\u5909\u7570\u306e\u3042\u3063\u305f\u6bdb\u69d8\u7d30\u80de\u6027\u661f\u7d30\u80de\u816b\u306b\uff0cBRAF\u963b\u5bb3\u5264 \u30d9\u30e0\u30e9\u30d5\u30a7\u30cb\u30d6\u304c\u6709\u52b9\u3067\u3042\u3063\u305f\u3053\u3068\u3092\u8a18\u8f09\u3057\u3066\u3044\u307e\u3059\u3002<\/span><\/p>\n<h4>dabrafenib\u3067\u9577\u671f\u5bdb\u89e3\u304c\u5f97\u3089\u308c\u305f\u30b0\u30ec\u30fc\u30c93 PXA<\/h4>\n<p>Amayiri N: Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma.\u00a0<span role=\"menubar\">Pediatr Hematol Oncol.<\/span> 2018<br \/>\nBRAF v600\u5909\u7570\u304c\u3042\u308a\uff0c\u64ad\u7a2e\u3057\u305fanaplastic PXA\u306b\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\u304c\u6295\u4e0e\u3055\u308c\u307e\u3057\u305f\u3002\u6295\u4e0e\u958b\u59cb\u5f8c2\u5e74\u306e\u6642\u70b9\u3067QOL\u304c\u826f\u3044\u72b6\u614b\u3067\u751f\u5b58\u3057\u3066\u3044\u308b\u3068\u306e1\u4f8b\u5831\u544a\u3067\u3059\u3002<\/p>\n<h4>\u30bf\u30d5\u30a3\u30f3\u30e9\u30fc\u3068\u30e1\u30ad\u30cb\u30b9\u30c8\u306e\u4f75\u7528\u7642\u6cd5\u304c\u60aa\u6027\u9ed2\u8272\u816b\u306e\u8133\u8ee2\u79fb\u306b\u6709\u52b9<\/h4>\n<p class=\"cit\">Davies MA: Dabrafenib plus trametinib in patients with <span class=\"highlight\">BRAF<\/span><sup>V600<\/sup>-mutant <span class=\"highlight\">melanoma<\/span> <span class=\"highlight\">brain<\/span> metastases (<span class=\"highlight\">COMBI-MB<\/span>): a multicentre, multicohort, open-label, phase 2 trial.\u00a0<span role=\"menubar\">Lancet Oncol.<\/span> 2017<br \/>\n\u30e1\u30e9\u30ce\u30fc\u30de\uff08\u60aa\u6027\u9ed2\u8272\u816b\uff09\u306b\u306f\uff0c\u30b0\u30ea\u30aa\u30fc\u30de\u3067\u3082\u307f\u3089\u308c\u308bBRAF v600\u3068\u3044\u3046\u907a\u4f1d\u5b50\u306e\u5909\u7570\u304c\u3042\u308a\u307e\u3059\u3002\u3053\u306e\u907a\u4f1d\u5b50\u306e\u50cd\u304d\u3092\u7279\u7570\u7684\u306b\u6291\u3048\u308b\u963b\u5bb3\u5264\uff0c\u30c0\u30d6\u30e9\u30d5\u30a7\u30cb\u30d6\u3068\u30c8\u30e9\u30e1\u30c1\u30cb\u30d6\u304c\u4f75\u7528\u3055\u308c\u307e\u3057\u305f\u3002\u30e1\u30e9\u30ce\u30fc\u30de\u306e\u8133\u8ee2\u79fb\u3092\u6709\u3059\u308b125\u4eba\u306e\u60a3\u8005\u3055\u3093\u306b\u6295\u4e0e\u304c\u884c\u308f\u308c\uff0c50-60%\u307b\u3069\u306e\u60a3\u8005\u3055\u3093\u3067\u8133\u8ee2\u79fb\u304c\u7e2e\u5c0f\u3057\u307e\u3057\u305f\u3002\u554f\u984c\u306f\u52b9\u679c\u306e\u6301\u7d9a\u6027\u3067\uff0c\u9577\u671f\u306e\u6709\u52b9\u6027\u306f\u306a\u3044\u3088\u3046\u3067\u3059\u3002<\/p>\n<h4>\u5c0f\u5150\u81a0\u82bd\u816b\u306e\u5206\u5b50\u30de\u30fc\u30ab\u30fc\u306f\u6210\u4eba\u3068\u7570\u306a\u308b\uff0c\u4e88\u5f8c\u304c\u826f\u3044\u3082\u306e\u304c\u3042\u308b<\/h4>\n<p>Korshunov A, et al.: Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol, 2015<br \/>\n20\u6b73\u672a\u6e80\u306e\u81a0\u82bd\u816b\u306e\u5206\u5b50\u89e3\u6790\u3067\u3059\u300220%\u3067methylation profiles\u304c\u4f4e\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u3084PXA \u306b\u985e\u4f3c\u3057\u3066\u3044\u3066\uff0c\u3053\u308c\u3089\u306e\u3082\u306e\u3067\u306f\uff0c\u751f\u547d\u4e88\u5f8c\u304c\u304b\u306a\u308a\u826f\u304b\u3063\u305f\u305d\u3046\u3067\u3059\u3002<span style=\"color: #000080;\"><strong>PXA\u69d8\u306e\u816b\u760d\u3067\u306fBRAF V600E\u5909\u7570<\/strong><\/span>\u3068CDKN2A\u306ehomozygous deletion\u304c\u3042\u308a\u307e\u3057\u305f\u3002\u6b8b\u308a\u306e80%\u3067\u306f\uff0cH3.3\u3084IDH\u306e\u5909\u7570\u304c\u898b\u3089\u308c\u3066\u3044\u307e\u3059\u3002IDH\u91ce\u751f\u578b\u306f36%\u3067\u3057\u305f\u3002\u6210\u4ebaGBM\u3067\u306f\uff0cIDH\u91ce\u751f\u578b\u304c\u307b\u3068\u3093\u3069\u3067\u3042\u308b\u306e\u3068\u5bfe\u7167\u7684\u306a\u30c7\u30fc\u30bf\u3067\u3059\u3002\u8907\u6570\u306e\u764c\u907a\u4f1d\u5b50\u306e\u5897\u5e45\u304c\u3042\u308b\u3082\u306e\u306f\u4e88\u5f8c\u4e0d\u826f\u3060\u305d\u3046\u3067\u3059\u3002<\/p>\n<h4>\u4e73\u982d\u72b6\u982d\u84cb\u54bd\u982d\u816b\u3067BRAF\u306e\u5909\u7570\u304c\u3042\u308b<\/h4>\n<p>Brastianos PK, et al.: Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46: 161-165, 2014<\/p>\n<h4><strong>BRAF V600E mutation\u304c\u3042\u308b\u3082\u306e\u306f\u4e88\u5f8c\u304c\u826f\u3044<\/strong><\/h4>\n<p>Ida CM, et al.: Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up. Brain Pathol 10: 2014<br \/>\n\u30e1\u30a4\u30e8\u30af\u30ea\u30cb\u30c3\u30af\u304b\u3089\u306e\u5831\u544a\u3067\u3059\u300274\u4eba\u306e\u60a3\u8005\u3055\u3093\u306e\u5e74\u9f62\u4e2d\u592e\u5024\u306f21\u6b73\u3067\u3057\u305f\u3002anaplasia\u3068\u3044\u3046\u306e\u306f\uff0c\u816b\u760d\u306b\u58ca\u6b7b\u304c\u3042\u308b\u304b\uff0c\u7d30\u80de\u306e\u5206\u88c2\u80fd\u304c\u9ad8\u3044(mitotic index &gt;5\/10HPF\uff09\u3053\u3068\u3068\u5b9a\u7fa9\u3057\u307e\u3057\u305f\u3002mitotic index\u306e\u9ad8\u3044\u4f8b\u306e\u307b\u3068\u3093\u3069\u306b\u58ca\u6b7b\u304c\u8a8d\u3081\u3089\u308c\u307e\u3057\u305f\u3002BRAF\u306e\u5909\u7570\u306f65% (39\/60)\u306b\u3042\u308a\uff0c\u5909\u7570\u306e\u7121\u3044\u4f8b\u3088\u308a\u660e\u3089\u304b\u306b\u751f\u5b58\u671f\u9593\u304c\u9577\u304b\u3063\u305f\u3068\u306e\u3053\u3068\u3067\u3059 (p=0.02)\u3002\u9006\u306b\uff0canaplasia\u304c\u3042\u308b\u60a3\u8005\u3055\u3093\u306e\u751f\u5b58\u671f\u9593\u306f\u77ed\u3044\u3068\u3055\u308c\u3066\u3044\u307e\u3059\u30023\u5e74\u4ee5\u5185\u306b\u6b7b\u4ea1\u3057\u305f\u60a3\u8005\u3055\u3093\u306f\uff0canaplasia\u304c\u3042\u308b\u304b\uff0c\u624b\u8853\u3067\u816b\u760d\u304c\u5168\u6458\u51fa\u3067\u304d\u3066\u3044\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/p>\n<h4>BRAF\u963b\u5bb3\u56e0\u5b50\u306e\u52b9\u679c<\/h4>\n<p>Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neurooncol, 2013<br \/>\n<span class=\"highlight\">BRAF<\/span> inhibitor\u3067\u3042\u308bvemurafenib\u304c4\u4f8b\u306e\u518d\u767a\u60a3\u8005\u3055\u3093\u3067\u52b9\u679c\u304c\u3042\u3063\u305f\u304b\u3082\u3057\u308c\u306a\u3044\u3068\u3044\u3046\u5831\u544a\u3067\u3059\u3002\u3053\u308c\u4ee5\u6765\uff0c\u8ffd\u8a66\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BRAF\u907a\u4f1d\u5b50\u306e\u7570\u5e38\u3067\u767a\u751f\u3059\u308b\u764c\u306b\u306f\uff0c\u60aa\u6027\u9ed2\u8272\u816b\uff0c\u6709\u6bdb\u7d30\u80de\u767d\u8840\u75c5\uff0c\u7532\u72b6\u817a\u30ac\u30f3\uff0c\u5927\u8178\u30ac\u30f3\u3084\u80ba\u30ac\u30f3\u304c\u6709\u540d\u3067\u3059 \u8133\u816b\u760d\u306b\u3082BRAF\u907a\u4f1d\u5b50\u306e\u7570\u5e38\u3067\u767a\u751f\u3059\u308b\u3082\u306e\u304c\u3042\u308b\u3053\u3068\u304c\u77e5\u3089\u308c\u3066\u304d\u307e\u3057\u305f \u7279\u306b\u5c0f\u5150\u306e\u8133\u816b\u760d\u3067BRAF\u306e\u907a\u4f1d\u5b50\u7570\u5e38\u306f [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,5],"tags":[],"class_list":["post-22589","post","type-post","status-publish","format-standard","hentry","category-glioma","category-pediattumor"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/posts\/22589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/comments?post=22589"}],"version-history":[{"count":12,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/posts\/22589\/revisions"}],"predecessor-version":[{"id":22592,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/posts\/22589\/revisions\/22592"}],"wp:attachment":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/media?parent=22589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/categories?post=22589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/tags?post=22589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}